Object Details
maker
Genentech, Inc.
Description (Brief)
(From box) For intravitreal injection only.
(From insert) LUCENTIS is indicated for the treatment of patients with:
--NEovascular (Wet) Age-Related Macular Degeneration
--Macular Edema Followign Retinal Vein Occlusion
--Diabetic Macular Edema
Location
Currently not on view
Credit Line
Gift of Genentech, Inc.
date made
ca 2013
product expiration date
2015-07
ID Number
2013.0069.07
catalog number
2013.0069.07
accession number
2013.0069
Object Name
pharmaceutical
biological
Physical Description
glass (overall material)
plastic (overall material)
metal (overall material)
paper (overall material)
cardboard (overall material)
Ranibizumab, 0.5 mg (overall ingredient)
Measurements
overall: 3/4 in x 2 5/8 in x 3 1/2 in; 1.905 cm x 6.6675 cm x 8.89 cm
bottle of lucentis: 1 1/2 in x 5/8 in; 3.81 cm x 1.5875 cm
filter needle: 3/4 in x 3 5/8 in x 1/4 in; 1.905 cm x 9.2075 cm x .635 cm
precisionglide needle: 3/4 in x 3 3/16 in x 1/4 in; 1.905 cm x 8.09625 cm x .635 cm
overall: 3 1/2 in x 2 1/2 in x 3/4 in; 8.89 cm x 6.35 cm x 1.905 cm
place made
United States: California, South San Francisco
See more items in
Medicine and Science: Medicine
Health & Medicine
The Antibody Initiative
Antibody Initiative: Monoclonal Antibodies
Data Source
National Museum of American History
Link to Original Record
Record ID
nmah_1445181